MGX Stock News & Catalysts – Metagenomi, Inc. Common Stock

FEATURED

Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting

MGX-001 data establish preclinical proof-of-concept in hemophilia AOn track to initiate global clinical trial in 2027 EMERYVILLE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX)

Summary

Nov 4, 2026, 9:25 AM ·Globe Newswire

RECENT

Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference

EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create

Oct 13, 2026, 8:00 AM ·Globe Newswire

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create

Sep 1, 2026, 8:00 AM ·Globe Newswire

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be

Aug 25, 2026, 10:13 AM ·PRNewswire

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and

Aug 10, 2026, 4:05 PM ·Globe Newswire

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today

Jul 15, 2026, 8:00 AM ·Globe Newswire

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Jun 5, 2026, 3:45 PM ·PRNewswire

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic

May 28, 2026, 8:00 AM ·Globe Newswire

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application ("IND") in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights

May 11, 2026, 4:05 PM ·Globe Newswire

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

EMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative

Apr 16, 2026, 7:00 AM ·Globe Newswire

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights.We would handle the matter on a contingent fee basis, whereby you would not be

Apr 13, 2026, 12:15 PM ·PRNewswire

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug

Mar 5, 2026, 4:05 PM ·Globe Newswire

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative

Feb 23, 2026, 4:05 PM ·Globe Newswire

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001

Jan 12, 2026, 8:30 AM ·Globe Newswire

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines

Dec 1, 2025, 7:00 AM ·Globe Newswire

Metagenomi, Inc. Common Stock MGX · News